Oncorus, Inc. (NASDAQ:ONCR) Sees Significant Increase in Short Interest

Oncorus, Inc. (NASDAQ:ONCRGet Rating) was the recipient of a large growth in short interest in the month of April. As of April 30th, there was short interest totalling 1,030,000 shares, a growth of 31.9% from the April 15th total of 780,800 shares. Currently, 6.4% of the shares of the company are short sold. Based on an average daily trading volume, of 138,600 shares, the short-interest ratio is presently 7.4 days.

ONCR has been the topic of a number of recent analyst reports. HC Wainwright initiated coverage on Oncorus in a research report on Monday, March 28th. They issued a “buy” rating and a $7.00 price target on the stock. Zacks Investment Research upgraded Oncorus from a “hold” rating to a “buy” rating and set a $1.25 price target on the stock in a research report on Wednesday, May 11th. Finally, Maxim Group decreased their price target on Oncorus from $20.00 to $7.00 in a research report on Thursday, March 10th.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Citigroup Inc. boosted its stake in Oncorus by 151.6% in the fourth quarter. Citigroup Inc. now owns 5,860 shares of the company’s stock valued at $31,000 after acquiring an additional 3,531 shares during the last quarter. Prosight Management LP grew its holdings in Oncorus by 10.8% during the third quarter. Prosight Management LP now owns 55,411 shares of the company’s stock valued at $518,000 after purchasing an additional 5,411 shares during the period. NEXT Financial Group Inc bought a new position in Oncorus during the fourth quarter valued at $40,000. Bank of New York Mellon Corp grew its holdings in Oncorus by 16.1% during the third quarter. Bank of New York Mellon Corp now owns 57,996 shares of the company’s stock valued at $542,000 after purchasing an additional 8,059 shares during the period. Finally, Wells Fargo & Company MN bought a new position in Oncorus during the fourth quarter valued at $47,000. Hedge funds and other institutional investors own 84.26% of the company’s stock.

Shares of ONCR stock traded up $0.03 during trading hours on Monday, hitting $1.19. 298 shares of the company’s stock traded hands, compared to its average volume of 128,520. Oncorus has a 12 month low of $1.03 and a 12 month high of $17.79. The stock’s 50 day simple moving average is $1.51 and its 200 day simple moving average is $3.77. The stock has a market cap of $30.80 million, a PE ratio of -0.43 and a beta of 4.27.

Oncorus (NASDAQ:ONCRGet Rating) last posted its quarterly earnings data on Wednesday, May 4th. The company reported ($0.69) earnings per share for the quarter, topping the consensus estimate of ($0.77) by $0.08. Equities analysts forecast that Oncorus will post -2.66 earnings per share for the current fiscal year.

Oncorus Company Profile (Get Rating)

Oncorus, Inc, a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers.

Featured Articles

Receive News & Ratings for Oncorus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncorus and related companies with MarketBeat.com's FREE daily email newsletter.